Amblyopia Clinical Trial
Official title:
Validation of the Eye Screeningtest GoCheckKids (GCK) for the Detection of Amblyopia Risk Factors in Toddlers in Flanders.
| NCT number | NCT05484453 |
| Other study ID # | S64113 |
| Secondary ID | |
| Status | Active, not recruiting |
| Phase | |
| First received | |
| Last updated | |
| Start date | August 4, 2021 |
| Est. completion date | May 2023 |
| Verified date | July 2022 |
| Source | Universitaire Ziekenhuizen Leuven |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
The aim is to validate the new GoCheck Kids application as automatic eye screener for preschool children (<3 years of age) at 'Child and Family' agency. Sensitivity, specificity, positive and negative predictive value of the GoCheck Kids screening tool are the endpoints of this study.
| Status | Active, not recruiting |
| Enrollment | 460 |
| Est. completion date | May 2023 |
| Est. primary completion date | May 31, 2022 |
| Accepts healthy volunteers | |
| Gender | All |
| Age group | 11 Months to 16 Months |
| Eligibility | Inclusion Criteria: - GoCheck Kids (GCK) evaluation at Child and Family Agency at the age between 11-16 months. Exclusion Criteria: - Allergy for the used cycloplegia cyclopentolate 0.5%. - Any history of ocular surgery - The time window between GCK measurement and the complete eye examination may not exceed 2 months. - The parents or legal representatives of the child do not understand or speak Dutch, French or English. |
| Country | Name | City | State |
|---|---|---|---|
| Belgium | UZ Leuven | Leuven |
| Lead Sponsor | Collaborator |
|---|---|
| Universitaire Ziekenhuizen Leuven |
Belgium,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Sensitivity | Sensitivity of GCK eye screener | Day 1 | |
| Primary | Specificity | Specificity of GCK eye screener | Day 1 | |
| Primary | Positive predictive value | Positive predictive value of GCK eye screener | Day 1 | |
| Primary | Negative predictive value | Negative predictive value of GCK eye screener | Day 1 |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04238065 -
A Clinical Trial of Caterna Virtual Reality Facilitating Treatment in Children With Amblyopia
|
N/A | |
| Completed |
NCT04432181 -
Comparison of Deviation Types Among Astigmatic Children With Or Without Amblyopia
|
||
| Terminated |
NCT02767856 -
Regimens of Intermittent Occlusion Therapy for Amblyopia in Children
|
N/A | |
| Completed |
NCT02458846 -
Efficacy of Visual Screening in Ontario
|
N/A | |
| Completed |
NCT01190813 -
Levodopa for the Treatment of Residual Amblyopia
|
Phase 3 | |
| Completed |
NCT01109459 -
Multimodal Physician Intervention to Detect Amblyopia
|
N/A | |
| Completed |
NCT04313257 -
Monocular Action Video Game Treatment of Amblyopia
|
N/A | |
| Completed |
NCT04315649 -
Effect of 3D Movie Viewing on Stereopsis in Strabismus and / or Anisometropic Amblyops
|
N/A | |
| Completed |
NCT05223153 -
OCT-A and Amblyopia
|
||
| Recruiting |
NCT05522972 -
Establishing New Treatment Approaches for Amblyopia: Perceptual Learning and Video Games
|
N/A | |
| Completed |
NCT01430247 -
Vision Screening for the Detection of Amblyopia
|
N/A | |
| Completed |
NCT02200211 -
Study of Binocular Computer Activities for Treatment of Amblyopia
|
N/A | |
| Recruiting |
NCT06429280 -
Clinical Data Registry of Amblyopia Patients on Luminopia Treatment
|
||
| Withdrawn |
NCT04959422 -
Assuring Ophthalmologic Follow up
|
N/A | |
| Active, not recruiting |
NCT05612568 -
5 Years of Eye Screening for ARF in Children Aged <3 Years in Flanders
|
||
| Recruiting |
NCT03655912 -
Binocular Visual Therapy and Video Games for Amblyopia Treatment.
|
N/A | |
| Recruiting |
NCT06150391 -
Evaluation of Amblyopia Protocols Using a Dichoptic Gabor Videogame Program
|
N/A | |
| Completed |
NCT03754153 -
Binocularly Balanced Viewing Study
|
N/A | |
| Withdrawn |
NCT02594358 -
Caffeine in Amblyopia Study
|
Phase 1/Phase 2 | |
| Terminated |
NCT02246556 -
Dichoptic Virtual Reality Therapy for Amblyopia in Adults
|
Phase 1 |